Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.42 |
| ▸ | NCK1 | P16333 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5683130 | 0.79 | ALOX5AP (0.45) | BACE1NPC1RAB9AALOX5APKCNH2 | |
| SCHEMBL24506591 | 0.76 | KDM4E (0.38) | BACE1NPC1RAB9A | |
| SCHEMBL24506592 | 0.76 | PDPK1 (0.38) | BACE1NPC1RAB9AALOX5APPDE10A | |
| SCHEMBL13552130 | 0.76 | HTT (0.41) | NPC1RAB9APDE10A | |
| SCHEMBL24506571 | 0.76 | TGFBR1 (0.38) | KCNH2SCN10APDE10A | |
| SCHEMBL22521368 | 0.76 | BACE1 (0.52) | BACE1NCK1PLAUNCF1NPC1 | |
| SCHEMBL22521385 | 0.75 | BACE1 (0.39) | BACE1NCK1PLAUNCF1NPC1 | |
| SCHEMBL25450494 | 0.75 | MET (0.36) | BACE1NPC1RAB9AALOX5AP | |
| SCHEMBL31119356 | 0.75 | PLAU (0.52) | BACE1NCK1PLAUNCF1NOS2 | |
| SCHEMBL2479182 | 0.75 | PLAU (0.52) | BACE1NCK1PLAUNCF1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | BACE1 1834/4885NCK1 2910/4885PLAU 3441/4885 |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | BACE1 1834/4885NCK1 2910/4885PLAU 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.